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ABSTRACT
Objectives: Vilazodone hydrochloride is a novel selective serotonin reuptake inhibitor (SSRI) used to treat major depressive disorders. There are only 
sparse data available to know about the SSRI’s and its association with colon cancer. This study aims to evaluate and compare the in vitro cytotoxic 
effect of vilazodone with 5-fluorouracil (5-FU) in HT-29 cell line.
Methods: Cell viability was tested by the 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay (Mosmann, 1983). Test sample 
and standard drug in variable concentrations were added to the HT-29 cell lines for incubation over 24 h under ideal conditions. After washing the 
test and standard drug sample from the well with saline, MTT was added and incubated for 4 h. Dimethyl sulfoxide of 1 ml was added in all wells after 
incubation with MTT. The absorbance at 570 nm was measured with an ultraviolet - spectrophotometer.
Results: The values were tabulated, and the graph was plotted to find the IC-50 value (inhibitory concentration at 50%)  which was struck at 
28.5 μg/ml and12. 8 μg/ml for vilazodone hydrochloride and 5-FU, respectively. 
Conclusion: The results show that vilazodone hydrochloride has good anticancer property comparable with 5-FU, which would probably play a role 
as a cytotoxic agent in tumor cells. The proposed mechanism of action could be by activation of caspase-3 enzyme, thereby increasing apoptosis and 
indicates its use in coexisting depression and colon carcinoma. Other mechanism includes suppression of oncogene p53, which can be confirmed by 
future studies. 
Keywords: Vilazodone hydrochloride, Colon cancer cell line, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay, Selective serotonin 
reuptake inhibitor.
INTRODUCTION
As per the WHO epidemiology data, “Cancer is a leading cause of 
death worldwide, accounting for 8.8 million deaths in 2015. The 
second leading cause of cancer death is colorectal cancer, accounting 
for 774,000 deaths worldwide” [1]. The treatment of colorectal 
cancer includes surgery, radiotherapy, and chemotherapy with 
fluoropyrimidines especially 5-fluorouracil (5-FU) combined with 
folinic acid and oxaliplatin [2]. Apart from these available treatments, 
antidepressants are also considerably valued in cancer therapy. In 
the past two decades, the use of antidepressants principally selective 
serotonin reuptake inhibitors (SSRI’s) in neoplastic diseases has 
noticeably increased because the majority of cancer patients suffer 
from depressed mood [3,4]. Distinctly, there is a query whether 
antidepressants promote or depress tumor growth in experimental 
animals and patients [5]. Citalopram and fluoxetine were found to 
suppress cell division in colonic tumor models (in vivo) of mice [6]. 
Paroxetine and fluoxetine were indeed found to induce apoptosis 
in lung cancer cells (A549), neuroblastoma cells (SKNAS), and 
medulloblastoma/rhabdomyosarcoma cells (TE671) [7,8]. On 
the contrary, it was studied that fluoxetine and paroxetine induce 
carcinogenesis and promotes the growth of ovarian and mammary 
tumor [9-11]. Diversely, preclinical studies in tumor implanted rats 
depict that SSRI’s neither have stimulatory nor an inhibitory effect 
on the growth of tumor [12]. Henceforth, this inconsistent and 
contradictory data warrants the need for multiple studies to analyze 
the association of antidepressants and cancer.
Vilazodone hydrochloride: It is a novel SSRI and partial agonist of the 
serotonin (5-hydroxytryptamine) -1A receptor, used to treat major 
depressive disorders [13]. Vilazodone was approved in 2011 by the 
United States - Food and Drug Administration and in August 2015 by 
Central Drugs Standard Control Organization - India for the treatment 
of major depressive disorder [14]. Major and most common adverse 
effects are being acute pancreatitis, sleep paralysis, diarrhea, nausea, 
and headache [15]. This being a new drug needs to be explored for its 
association with colon cancer cells.
Aims and objectives
The aim of the study was to evaluate and compare the effect of 
vilazodone hydrochloride with 5-FU in the HT-29 colon cancer cell line 
in vitro using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide (MTT) assay.
Principle of MTT assay
This colorimetric assay measures the viable cells when the pale yellow 
MTT dye is acted on by the mitochondrial dehydrogenase enzyme which, 
in turn, cleaves the tetrazolium ring of MTT resulting in the formation of 
insoluble and impermeable dark purple colored formazan crystals [16].
METHODS
Cell Line and Culture
HT-29 cell lines used in the experiment were obtained from National 
Centre for Cell Sciences, Pune. The cells were maintained in minimal 
essential medium (MEM) supplemented with 10% fetal bovine serum, 
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penicillin (100 U/ml), and streptomycin (100μg/ml) in a humidified 
atmosphere of 50 μg/ml CO2 at 37°C.
PROCEDURE - MTT ASSAY: MOSMANN, 1983
Cells (1 × 105/well) were plated and maintained at 37°C with 5% CO2 
condition. After attaining confluent stage, samples (Vilazodone and 
5-FU) of various concentrations were added and incubated for 24 h. 
The sample was removed from the well after the incubation period, 
and the cells were bathed with phosphate-buffered saline (pH 7.4) or 
MEM without serum. MTT was added to the cells at a concentration of 
100 µl/well (5 mg/ml) and incubated for 4 h. 1 ml of dimethyl sulfoxide 
(DMSO) was added after 4 h of incubation in all the wells. Keeping DMSO 
as the blank all the test samples were measured with an ultraviolet - 
spectrophotometer at an absorbance of 570 nm. Readings were plotted 
and the inhibitory concentration at 50% (IC50) was determined 




A  of treated cells
% Cell viability   100
A of control cells 
= × 
% Cytotoxicity 100  % cell viability= −
Graphs were plotted to represent percentage of cell cytotoxicity at 
Y-axis against the concentration of the sample in X-axis.
RESULTS
The percentage cytotoxicity of vilazodone hydrochloride and 5-FU at 
various concentrations is as shown in Tables 1 and 2, respectively. It 
implies that as the dose increases, the percentage viability decreases. 
Accordingly, the IC50 value of vilazodone hydrochloride was espied 
at 28.5 μg/ml and depicted in Fig. 1 and the IC50 value was 5-FU 
ascertained at 12.8 μg/ml and depicted in Fig. 2.
Table 1: Cytotoxic effect of vilazodone on HT-29 cell line
S. No. Concentration (µg/ml) Dilutions Absorbance (O.D) Cell viability (%) Cell death (%)
1 1000 Neat 0.029 5.66 94.34
2 500 1:1 0.050 9.76 90.24
3 250 1:2 0.097 18.94 81.06
4 125 1:4 0.134 26.17 73.83
5 62.5 1:8 0.183 35.74 64.26
6 31.2 1:16 0.224 43.75 56.25
7 15.6 1:32 0.281 54.88 45.12
8 7.8 1:64 0.315 61.52 38.48
9 Cell control - 0.512 100 0
O.D : Optical density
Table 2: Cytotoxic effect of 5-FU on HT-29 cell line
S. No. Concentration (µg/ml) Dilutions Absorbance (O.D) Cell viability (%) Cell death (%)
1 1000 Neat 0.011 4.9 95.1
2 500 1:1 0.042 8.20 91.80
3 250 1:2 0.080 15.62 84.38
4 125 1:4 0.104 20.31 79.69
5 62.5 1:8 0.148 28.90 71.10
6 31.2 1:16 0.176 34.37 65.63
7 15.6 1:32 0.212 41.40 58.60
8 7.8 1:64 0.72 53.12 46.88
9 Cell control - 0.512 100 0
5-FU: 5-flurouracil, O.D : Optical density
Fig. 1: IC-50 value (Inhibitory concentration at 50%)  of vilazodone hydrochloride
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DISCUSSION
Apart from modulating neurotransmission, antidepressant drugs have 
been noted to comport a range of effects, namely, immunomodulation, 
anti-oxidant, neuroprotection, analgesic, and anti-inflammatory 
activities, which are due to its influence on glial cell function [18,19]. At 
present, the scientific community has thrown its light to know about the 
possible anticancer activity of SSRI’s and found that these drugs alter the 
pivotal cellular mechanism of carcinogenesis [20]. The SSRI’s sertraline 
and paroxetine have been explorated to have anticancer property by 
arresting the cell division at G0 and G1 phase and by inflating caspase-3 
activity in the colon cancer cells [20-22]. Fluoxetine exhibited features 
of cell death and anti-proliferation of in vitro neuroblastoma cells 
(SKNAS), Burkitt’s lymphoma and breast cancer cells (T47D) [6,23,24]. 
Further, it was also added that fluoxetine-induced changes in the 
mitochondrial membrane permeability of human epithelial ovarian 
cells which resulted in the production of reactive oxygen species and 
ultimately cell death [24-27]. Correspondingly, our study also infers 
that vilazodone hydrochloride has got the good cytotoxic effect which is 
comparable and nearly equipotent with 5-FU in colon cancer cell lines 
which could be by activation of the Caspase-3 enzyme.
CONCLUSION
Our study advocates that the novel SSRI, vilazodone hydrochloride 
has potential cytotoxic effect against the colon cancer cells. As therapy 
with SSRI is usually indicated in cancer patients, the benefit of using 
vilazodone hydrochloride in colon cancer patients coupled with 
depression appears to be attractive.
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